The neurobiology of Alzheimer disease defined by neuroimaging

Current Opinion in Neurology

Volumn 25, Issue 4, 2012, Pages 410-420

  Masdeu, Joseph C ^a   Kreisl, William C ^b   Berman, Karen F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alzheimer disease; Amyloid ; Magnetic resonance imaging; Mild cognitive impairment; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BAPINEUZUMAB; CYSTEINE ETHYL ESTER TC 99M; FLORBETAPIR F 18; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; ANISOTROPY; BOLD SIGNAL; BRAIN ATROPHY; DEMENTIA; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFLAMMATION; MILD COGNITIVE IMPAIRMENT; NEUROBIOLOGY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANISOTROPY; ATROPHY; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; ENCEPHALITIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEUROBIOLOGY; NEUROIMAGING;

EID: 84863723011     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283557b36     Document Type: Review

References (133)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280-292.
2. Jagust W. Mapping brain beta-amyloid. Curr Opin Neurol 2009; 22:356-361.
3. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-128.
4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270-279.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-269.
6. Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 2012. doi:10.1001/archneurol.2011.3152. [Epub ahead of print]
7. Logothetis NK. What we can do and what we cannot do with fMRI. Nature 2008; 453:869-878. (Pubitemid 351832564)
8. Rocher AB, Chapon F, Blaizot X, et al. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003; 20:1894-1898. (Pubitemid 37468295)
9. Fox PT, Raichle ME, Mintun MA, et al. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988; 241:462-464.
10. Masdeu JC, Arbizu J. Brain single photon emission computed tomography: technological aspects and clinical applications. Semin Neurol 2008; 28:423-434.
11. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004; 45:594-607. (Pubitemid 47618590)
12. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009; 30:404-410.
13. Chen Y, Wolk DA, Reddin JS, et al. Voxel-level comparison of arterial spinlabeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011; 77:1977-1985.
14. Apostolova LG, Hwang KS, Medina LD, et al. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 32:118-125.
15. Knight WD, Kim LG, Douiri A, et al. Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol Aging 2011; 32:1765-1773.
16. Ringman JM, Pope W, Salamon N. Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease. J Neurol 2010; 257:839-842.
17. Fortea J, Sala-Llonch R, Bartres-Faz D, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis 2010; 22:909-922.
18. Crivello F, Lemaitre H, Dufouil C, et al. Effects of ApoE-varepsilon4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons. Neuroimage 2010; 53:1064-1069. doi: 10.1016/j.neuroimage.2009.12.116.
19. Mueller SG, Weiner MW. Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus 2009; 19:558-564.
20. Burggren AC, Zeineh MM, Ekstrom AD, et al. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 2008; 41:1177-1183.
21. Donix M, Burggren AC, Suthana NA, et al. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage 2010; 53:37-43.
22. Chiang GC, Insel PS, Tosun D, et al. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology 2011; 259:844-851.
23. Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69:1032-1042.
24. Chetelat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012; 78:477-484.
25. Putcha D, Brickhouse M, O'Keefe K, et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in nondemented elderly adults. J Neurosci 2011; 31:17680-17688.
26. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67:317-324.
27. Wolz R, Julkunen V, Koikkalainen J, et al. Multimethod analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One 2011; 6:e25446.
28. Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011; 56:52-60.
29. Heister D, Brewer JB, Magda S, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77:1619-1628.
30. Hua X, Leow AD, Parikshak N, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 2008; 43:458-469.
31. Urs R, Potter E, Barker W, et al. Visual rating system for assessing magnetic resonance images: a tool in the diagnosis of mild cognitive impairment and Alzheimer disease. J Comput Assist Tomogr 2009; 33:73-78.
32. Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1:13-21. (Pubitemid 37159194)
33. Wang L, Khan A, Csernansky JG, et al. Fully-automated, multistage hippocampus mapping in very mild Alzheimer disease. Hippocampus 2009; 19:541-548.
34. Morra JH, Tu Z, Apostolova LG, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009; 45:S3-S15.
35. McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009; 251:195-205.
36. Kloppel S, Stonnington CM, Barnes J, et al. Accuracy of dementia diagnosis: a direct comparison between radiologists and a computerized method. Brain 2008; 131:2969-2974.
37. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132:195-203.
38. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71:743-749.
39. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008; 42:559-567.
40. Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003; 23:994-1005. (Pubitemid 36206191)
41. Pascual B, Prieto E, Arbizu J, et al. Decreased 11C-flumazenil binding in early Alzheimer disease. J Neuroimag 2012; 22:106.
42. Ringman JM, O'Neill J, Geschwind D, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007; 130:1767-1776. (Pubitemid 47343801)
43. Smith CD, Chebrolu H, Andersen AH, et al. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging 2010; 31:1122-1131.
44. Douaud G, Jbabdi S, Behrens TE, et al. DTI measures in crossingfibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. Neuroimage 2011; 55:880-890.
45. Stricker NH, Schweinsburg BC, Delano-Wood L, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 2009; 45:10-16.
46. Fellgiebel A, Wille P, Muller MJ, et al. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 2004; 18:101-108. (Pubitemid 38822746)
47. Agosta F, Pievani M, Sala S, et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 2011; 258:853-863.
48. Mielke MM, Kozauer NA, Chan KC, et al. Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neuroimage 2009; 46:47-55.
49. Kiuchi K, Morikawa M, Taoka T, et al. Abnormalities of the uncinate fasciculus and posterior cingulate fasciculus in mild cognitive impairment and early Alzheimer's disease: a diffusion tensor tractography study. Brain Res 2009; 1287:184-191.
50. Kantarci K, Avula R, Senjem ML, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 2010; 74:1814-1821.
51. Clerx L, Visser PJ, Verhey F, et al. NewMRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 2012; 29:405-429.
52. Wee CY, Yap PT, Zhang D, et al. Identification of MCI individuals using structural and functional connectivity networks. Neuroimage 2012; 59:2045-2056.
53. O'Dwyer L, Lamberton F, Bokde AL, et al. Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One 2012; 7:e32441.
54. Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69:871-877. (Pubitemid 47329586)
55. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758. (Pubitemid 26089356)
56. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004; 101:284-289. (Pubitemid 38084242)
57. Miettinen PS, Pihlajamaki M, Jauhiainen AM, et al. Structure and function of medial temporal and posteromedial cortices in early Alzheimer's disease. Eur J Neurosci 2011; 34:320-330.
58. Bozoki AC, Korolev IO, Davis NC, et al. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: a DTI/FDGPET Study. Hum Brain Mapp 2011. doi:10.1002/hbm.21320. [Epub ahead of print]
59. Drzezga A, Becker JA, Van Dijk KR, et al. Neuronal dysfunction and disconnection of cortical hubs in nondemented subjects with elevated amyloid burden. Brain 2011; 134:1635-1646.
60. Chetelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008; 131:60-71.
61. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286:2120-2127. (Pubitemid 34041597)
62. Caroli A, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 2012; 53:592-600. doi: 10.2967/jnumed.111.094946.
63. Mosconi L, Brys M, Glodzik-Sobanska L, et al. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007; 42:129-138. (Pubitemid 44937821)
64. Boles Ponto LL, Magnotta VA, Moser DJ, et al. Global cerebral blood flow in relation to cognitive performance and reserve in subjects with mild memory deficits. Mol Imaging Biol 2006; 8:363-372. (Pubitemid 44741374)
65. Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 2005; 236:55-64. (Pubitemid 41218693)
66. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50:1563-1571. (Pubitemid 28283219)
67. Jagust W, Thisted R, Devous MD Sr, et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001; 56:950-956. (Pubitemid 32290814)
68. Devanand DP, Van Heertum RL, Kegeles LS, et al. (99m)Tc hexamethylpropylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease. Am J Geriatr Psychiatry 2010; 18:959-972.
69. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343:450-456. (Pubitemid 30646483)
70. Bondi MW, Houston WS, Eyler LT, et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005; 64:501-508. (Pubitemid 40189870)
71. Trivedi MA, Schmitz TW, Ries ML, et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease. Neuropsychologia 2008; 46:1667-1678.
72. Fleisher AS, Houston WS, Eyler LT, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol 2005; 62:1881-1888. (Pubitemid 41785082)
73. Mondadori CR, de Quervain DJ, Buchmann A, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex 2007; 17:1934-1947. (Pubitemid 47216511)
74. Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 2006; 26:6069-6076. (Pubitemid 44334754)
75. Nichols L, Masdeu J, Mattay V, et al. Hippocampal activation during episodic memory processing in healthy adult apolipoprotein E e4 carriers is significantly influenced by age. Arch Gen Psychiatry (in press).
76. Braskie MN, Medina LD, Rodriguez-Agudelo Y, et al. Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. Neurobiol Aging 2012; 33:424.e11-424.e21.
77. Quiroz YT, Budson AE, Celone K, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol 2010; 68:865-875.
78. Ringman JM, Medina LD, Braskie M, et al. Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. Cereb Cortex 2011; 21:877-883.
79. Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56:27-35. (Pubitemid 38857357)
80. O'Brien JL, O'Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74:1969-1976.
81. Filippi M, Agosta F. Structural and functional network connectivity breakdown in Alzheimer's disease studied with magnetic resonance imaging techniques. J Alzheimers Dis 2011; 24:455-474.
82. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromol Med 2010; 12:27-43.
83. Power JD, Barnes KA, Snyder AZ, et al. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012; 59:2142-2154.
84. Dennis NA, Browndyke JN, Stokes J, et al. Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement 2010; 6:303-311.
85. Gour N, Ranjeva JP, Ceccaldi M, et al. Basal functional connectivity within the anterior temporal network is associated with performance on declarative memory tasks. Neuroimage 2011; 58:687-697.
86. Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29:12686-12694.
87. Jacobs HI, Van Boxtel MP, Heinecke A, et al. Functional integration of parietal lobe activity in early Alzheimer disease. Neurology 2012; 78:352-360.
88. Machulda MM, Jones DT, Vemuri P, et al. Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol 2011; 68:1131-1136.
89. Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci 2010; 30:17035-17040.
90. Galvin JE, Price JL, Yan Z, et al. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 2011; 76:1797-1803.
91. Kenny ER, Blamire AM, Firbank MJ, et al. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain 2012; 135:569-581.
92. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011; 134:301-317.
93. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 2011; 52:1733-1740.
94. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68:1398-1403.
95. Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012; 26:8-16.
96. Shin J, Kepe V, Barrio JR, et al. The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 2011; 26:135-145.
97. Tolboom N, van der Flier WM, Boverhoff J, et al. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of (11)C PIB and (18)F FDDNP PET images. J Neurol Neurosurg Psychiatry 2010; 81:882-884.
98. Shin J, Lee SY, Kim SJ, et al. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 2010; 52:488-496.
99. Ercoli LM,WSmallG, Siddarth P, et al. Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging. Int J Geriatr Psychiatry 2012. doi:10.1002/gps.2816. [Epub ahead of print]
100. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645. (Pubitemid 351806448)
101. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007; 64:431-434. (Pubitemid 46425701)
102. Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011; 68:1526-1535.
103. Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [(11)C]PIB, [(18)F]FDDNP and [(18)F]FDG PET. Eur J Nucl Med Mol Imaging 2012; 39:990-1000. doi: 10.1007/s00259-012-2102-3.
104. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665-680. (Pubitemid 351294719)
105. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69:181-192.
106. Chetelat G, Villemagne VL, Pike KE, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 2012; 10:141-144. doi: 10.1159/000334295.
107. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment. A 2-year follow-up study. Neurology 2011; 76:1085-1090.
108. Perrotin A, Mormino EC, Madison CM, et al. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 2012; 69:223-229.
109. Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B ((11)CPIB) and Fluorodeoxyglucose ((18)F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010; 23:185-198.
110. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132:1310-1323.
111. Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011; 70:857-861.
112. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3:89ra57.
113. Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol 2012; 69:623-629. doi: 10.1001/archneurol.2011.2748.
114. Head D, Bugg JM, Goate AM, et al. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol 2012; 69:636-643. doi: 10.1001/archneurol.2011.845.
115. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11:241-249.
116. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73:754-760.
117. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568.
118. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133:3336-3348.
119. Small GW, Siddarth P, Kepe V, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69:215-222.
120. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034-2042.
121. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 2011; 8:164-174.
122. Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol 2011; 179:1373-1384.
123. Hoozemans JJM, Rozemuller AJM, van Haastert ES, et al. Neuroinflammation in Alzheimer's disease wanes with age. J Neuroinflammation 2011; 8:171.
124. Kropholler MA, Boellaard R, van Berckel BNM, et al. Evaluation of reference regions for (R)-C-11 PK11195 studies in Alzheimer's disease andmild cognitive impairment. J CerebBlood FlowMetab 2007; 27:1965-1974. (Pubitemid 350129158)
125. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; 72:56-62.
126. Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010; 49:2924-2932.
127. Chauveau F, Boutin H, Van Camp N, et al. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008; 35:2304-2319.
128. Maeda J, Zhang MR, Okauchi T, et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci 2011; 31:4720-4730.
129. Gulyas B, Vas A, Toth M, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with C-11 vinpocetine. Neuroimage 2011; 56:1111-1121.
130. Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 2012; 53:37-46.
131. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367-385.
132. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69:198-207.
133. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14:11-20. (Pubitemid 38200585)